Synectics Regulatory News (SNX)

5 Feb 2007 07:00

Synexus Clinical Research PLC05 February 2007 Synexus Clinical Research plc Appointment of Alan Boyce as Chief Operating Officer Synexus, the provider of Clinical Research Services for the pharmaceuticalindustry, is pleased to announce that Alan Boyce has been appointed to the Boardas Chief Operating Officer with effect from 19 February. Alan, aged 45, has previously been the Vice-President of Operations, Europe,Middle East and Africa for the US Clinical Research Organisation, Kendle. Inthis position he has successfully built the European operations of the companyinto an organisation with substantial revenues, and 1300 employees across thevarious countries. He led the integration in Europe of Charles RiverLaboratories, acquired by Kendle. Prior to his position with Kendle, Alan spent 18 years in the pharmaceuticaldivision of Procter and Gamble, working both in the UK and the USA, culminatingin the position of Commercial Director, UK and Ireland of P & G Pharmaceuticals. Commenting on his appointment, Synexus' CEO Michael Fort said: - "Alan brings major operational experience of both a provider of clinicalresearch services to the pharmaceutical industry, and of the pharma industryitself. This expertise will be invaluable in building and integrating theexpanding operations of Synexus". Other than as set out below, there is no additional information required to bedisclosed under Schedule 2(g) of the AIM Rules: Alan Boyce is currently director of Kendle International Holdings Limited andKendle Clinical Development Services Limited. In the last five years, he wasalso director of Cambrian Close Pump Management Limited. Enquiries: Synexus Clinical Research plc Tel: +44 (0)1257 230 723Michael Fort, Chief Executive Biddicks - Financial Public Relations Tel: +44 (0)20 7448 1000Zoe Biddick This information is provided by RNS The company news service from the London Stock Exchange